查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1612195

抗體片段市場：按類型、抗體類型、應用分類 - 全球預測 2025-2030

Antibody Fragments Market by Type (F(ab) Fragments, F(ab')2 Fragments, Single Domain Antibody Fragments (sdAbs)), Antibody Type (Monoclonal, Polyclonal), Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年抗體片段市值為77.2億美元，預計2024年將達到80.7億美元，複合年成長率為4.36%，預計2030年將達到104.2億美元。

抗體片段代表了生物技術領域的一個重要類別，由單株抗體的小片段組成，與全尺寸抗體相比，具有更強的靶向能力和更少的副作用。這些片段的市場是由它們在標靶藥物傳輸和癌症治療等治療方法中的應用所推動的，因為它們的小尺寸使它們能夠更有效地穿透腫瘤。慢性病的增加增加了對片段的需求，這些片段可以提供比傳統單株抗體療法更有效、在某些情況下更便宜的替代品。這些片段在診斷影像、感染疾病治療和生物製藥偶聯物等多種領域有著強大的應用。最終用途多種多樣，包括醫院、專科診所和專注於開發新治療方法和診斷方法的研究機構。

主要市場統計
基準年[2023] 77.2億美元
預測年份 [2024] 80.7億美元
預測年份 [2030] 104.2億美元
複合年成長率（%） 4.36%

市場開拓洞察揭示了影響成長的幾個因素，包括精準醫療需求的激增、基因工程的技術進步以及研發投資的增加。生物相似藥市場的擴張和監管機構核准的新生技藥品數量的增加代表著潛在的商機。公司可以透過投資雙特異性抗體和單域抗體片段等創新技術來抓住這些機會。然而，市場也有限制因素。特別是與研究和製造流程相關的高成本、智慧財產權挑戰以及嚴格的監管要求可能會阻礙快速進入市場。

為了推動業務成長，產業參與者應專注於多標靶治療方法開發的創新和改善片段半衰期以提高治療效果。使用非規範胺基酸的綴合技術的研究和新型支架的探索可能會導致片段工程的突破。抗體片段市場的高度動態和競爭性需要結合強大的研發計劃和策略夥伴關係關係，以克服挑戰，同時利用新機會。對個人化醫療和精準治療計劃的重視可能會進一步提高市場滲透率並推動永續成長。

市場動態：揭示快速發展的抗體片段市場的關鍵市場洞察

抗體片段市場正因供需的動態交互作用而轉變。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 抗體片段在醫學診斷上的使用越來越多
    • 各種癌症和感染疾病的增加
    • 藥物發現活動的增加
  • 市場限制因素
    • 抗體片段核准的嚴格監管指南
  • 市場機會
    • 抗體片段臨床開發進展
    • 先進重組DNA技術簡介
  • 市場挑戰
    • 抗癌免疫療法療效不足且副作用大

波特五力：駕馭抗體片段市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解抗體片段市場的外部影響

外部宏觀環境因素對抗體片段市場的表現動態起著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解抗體片段市場的競爭格局

抗體片段市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣抗體片段市場廠商績效評估

FPNV定位矩陣是評估抗體片段市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議繪製抗體片段市場的成功之路

抗體片段市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 抗體片段在醫學診斷的使用增加
      • 各種癌症和感染疾病的發生率增加
      • 藥物發現活動的增加
    • 抑制因素
      • 抗體片段核准的嚴格監管指南
    • 機會
      • 抗體片段臨床開發進展
      • 先進重組DNA技術簡介
    • 任務
      • 抗癌免疫療法療效不足且副作用大
  • 市場區隔分析
    • 類型：由於結合穩定性和靈活性，從應用角度來看，單域抗體片段（sdAb）的使用正在迅速增加
    • 抗體類型：標靶治療的高特異性擴大了單株抗體的用途
    • 應用：抗體片段在癌症治療中應用的演變
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章抗體片段市場：依類型

  • F(ab) 片段
  • F(ab')2 片段
  • 單域抗體片段 (sdAb)
  • 單鏈可變片段（scFv）

第7章 依抗體類型分類的抗體片段市場

  • 單複製
  • 多克隆抗體

第8章抗體片段市場：依應用分類

  • 癌症
  • 免疫力缺乏

第9章美洲抗體片段市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太抗體片段市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲抗體片段市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Lupin 和 Amman Pharma 合作獨家經銷雷珠單抗
    • 伯明罕血小板集團推出突破性「奈米抗體」技術
    • Atovia 是一家加州新創生技公司，其成立的目的是重新思考藥物如何與其標靶結合。
  • 戰略分析和建議

公司名單

  • AbbVie Inc.
  • Adaptimmune Therapeutics PLC
  • Aenova Group GmbH
  • Almac Group
  • Amgen Inc.
  • Antikor Biopharma
  • Astellas Pharma Inc.
  • Baxter International Inc.
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Confo Therapeutics
  • Dyne Therapeutics
  • Eli Lilly and Company
  • Evonik Industries AG
  • F. Hoffmann-La Roche Ltd.
  • Genentech, Inc.
  • Gilde Healthcare
  • Johnson & Johnson Services, Inc.
  • MoonLake Immunotherapeutics AG
  • Novartis AG
  • Numab AG
  • Pfizer Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Thermo Fisher Scientific Inc.
Product Code: MRR-F927BA461FE0

The Antibody Fragments Market was valued at USD 7.72 billion in 2023, expected to reach USD 8.07 billion in 2024, and is projected to grow at a CAGR of 4.36%, to USD 10.42 billion by 2030.

Antibody fragments represent a prominent category within the biotechnology landscape, consisting of smaller segments of monoclonal antibodies with enhanced targeting capabilities and fewer side effects compared to full-sized antibodies. The market for these fragments is driven by their application in therapeutic methods, such as targeted drug delivery and cancer treatment, as they can infiltrate tumors more effectively due to their smaller size. A significant necessity arises from the increasing prevalence of chronic diseases, with fragments offering more efficient and sometimes less costly alternatives to traditional monoclonal antibody therapies. These fragments find robust applications across diverse sectors, including diagnostic imaging, the treatment of infectious diseases, and as biopharmaceutical conjugates. The end-use spectrum spans hospitals, specialty clinics, and research institutes focused on developing novel cures and diagnostic methods.

KEY MARKET STATISTICS
Base Year [2023] USD 7.72 billion
Estimated Year [2024] USD 8.07 billion
Forecast Year [2030] USD 10.42 billion
CAGR (%) 4.36%

Market insights reveal several factors influencing growth, such as the burgeoning demand for precision medicine, technological advancements in genetic engineering, and escalating research and development investments. Potential opportunities materialize from the expanding biosimilars market and the rising approval of novel biologics by regulatory bodies. Companies can seize these opportunities by investing in innovative technologies like bispecific antibodies and single-domain antibody fragments. However, the market also faces limitations, notably the high costs associated with research and manufacturing processes, intellectual property challenges, and stringent regulatory requirements that could hinder swift market entry.

To foster business growth, industry players should focus on innovation in developing multi-targeted therapies and improving fragment half-life to boost therapeutic efficacy. Research into non-canonical amino acids for conjugation techniques and exploring novel scaffolds can lead to breakthroughs in fragment engineering. The nature of the antibody fragment market is highly dynamic and competitive, necessitating a blend of robust R&D initiatives and strategic partnerships to navigate challenges while leveraging emerging opportunities. Emphasizing personalized medicine and precision treatment plans could further enhance market penetration and drive sustained growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Antibody Fragments Market

The Antibody Fragments Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing use of antibody fragments in medical diagnostics
    • Rising incidences of various cancers and infectious diseases
    • Increasing number of drug discovery activities
  • Market Restraints
    • Strict regulatory guidelines for the approval of antibody fragments
  • Market Opportunities
    • Advancements in the clinical development of antibody fragments
    • Introduction of advanced recombinant DNA technology
  • Market Challenges
    • Insufficient efficacy and adverse effects in anticancer immunotherapy

Porter's Five Forces: A Strategic Tool for Navigating the Antibody Fragments Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Antibody Fragments Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Antibody Fragments Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Antibody Fragments Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Antibody Fragments Market

A detailed market share analysis in the Antibody Fragments Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Antibody Fragments Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Antibody Fragments Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Antibody Fragments Market

A strategic analysis of the Antibody Fragments Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Antibody Fragments Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Adaptimmune Therapeutics PLC, Aenova Group GmbH, Almac Group, Amgen Inc., Antikor Biopharma, Astellas Pharma Inc., Baxter International Inc., Biogen Inc., Bristol-Myers Squibb Company, Confo Therapeutics, Dyne Therapeutics, Eli Lilly and Company, Evonik Industries AG, F. Hoffmann-La Roche Ltd., Genentech, Inc., Gilde Healthcare, Johnson & Johnson Services, Inc., MoonLake Immunotherapeutics AG, Novartis AG, Numab AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Antibody Fragments Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across F(ab) Fragments, F(ab')2 Fragments, Single Domain Antibody Fragments (sdAbs), and Single-chain Variable Fragments (scFvs).
  • Based on Antibody Type, market is studied across Monoclonal and Polyclonal.
  • Based on Application, market is studied across Cancer and Immunodeficiencies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing use of antibody fragments in medical diagnostics
      • 5.1.1.2. Rising incidences of various cancers and infectious diseases
      • 5.1.1.3. Increasing number of drug discovery activities
    • 5.1.2. Restraints
      • 5.1.2.1. Strict regulatory guidelines for the approval of antibody fragments
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in the clinical development of antibody fragments
      • 5.1.3.2. Introduction of advanced recombinant DNA technology
    • 5.1.4. Challenges
      • 5.1.4.1. Insufficient efficacy and adverse effects in anticancer immunotherapy
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Burgeoning usage of single domain antibody fragments (sdAbs) in terms of applications due to their stability and flexibility in binding
    • 5.2.2. Antibody Type: Proliferating utilization of monoclonal antibodies owing to their high specificity in targeted therapeutics
    • 5.2.3. Application: Evolving application of antibody fragments in cancer therapy
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Antibody Fragments Market, by Type

  • 6.1. Introduction
  • 6.2. F(ab) Fragments
  • 6.3. F(ab')2 Fragments
  • 6.4. Single Domain Antibody Fragments (sdAbs)
  • 6.5. Single-chain Variable Fragments (scFvs)

7. Antibody Fragments Market, by Antibody Type

  • 7.1. Introduction
  • 7.2. Monoclonal
  • 7.3. Polyclonal

8. Antibody Fragments Market, by Application

  • 8.1. Introduction
  • 8.2. Cancer
  • 8.3. Immunodeficiencies

9. Americas Antibody Fragments Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Antibody Fragments Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Antibody Fragments Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Lupin, Amman Pharma Collaborates for Exclusive Marketing of Ranibizumab
    • 12.3.2. Birmingham Platelet Group Delivers Breakthrough 'nanobody' Technology
    • 12.3.3. Attovia, a new California biotech, Launches with Plans to Rethink how Drugs Bind their Targets
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Adaptimmune Therapeutics PLC
  • 3. Aenova Group GmbH
  • 4. Almac Group
  • 5. Amgen Inc.
  • 6. Antikor Biopharma
  • 7. Astellas Pharma Inc.
  • 8. Baxter International Inc.
  • 9. Biogen Inc.
  • 10. Bristol-Myers Squibb Company
  • 11. Confo Therapeutics
  • 12. Dyne Therapeutics
  • 13. Eli Lilly and Company
  • 14. Evonik Industries AG
  • 15. F. Hoffmann-La Roche Ltd.
  • 16. Genentech, Inc.
  • 17. Gilde Healthcare
  • 18. Johnson & Johnson Services, Inc.
  • 19. MoonLake Immunotherapeutics AG
  • 20. Novartis AG
  • 21. Numab AG
  • 22. Pfizer Inc.
  • 23. Sanofi S.A.
  • 24. Takeda Pharmaceutical Company Limited
  • 25. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. ANTIBODY FRAGMENTS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTIBODY FRAGMENTS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES ANTIBODY FRAGMENTS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES ANTIBODY FRAGMENTS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ANTIBODY FRAGMENTS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. ANTIBODY FRAGMENTS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTIBODY FRAGMENTS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTIBODY FRAGMENTS MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY F(AB) FRAGMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY F(AB')2 FRAGMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY SINGLE DOMAIN ANTIBODY FRAGMENTS (SDABS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY SINGLE-CHAIN VARIABLE FRAGMENTS (SCFVS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY MONOCLONAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY POLYCLONAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY IMMUNODEFICIENCIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES ANTIBODY FRAGMENTS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. ANTIBODY FRAGMENTS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 146. ANTIBODY FRAGMENTS MARKET, FPNV POSITIONING MATRIX, 2023